Arcutis Biotherapeutics (ARQT) Total Current Liabilities (2019 - 2026)

Arcutis Biotherapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $163.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 79.09% year-over-year to $163.2 million; the TTM figure through Mar 2026 stood at $163.2 million (up 79.09% YoY), while the FY2025 annual figure was $129.8 million, up 60.27% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $163.2 million, up from $129.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $172.4 million in Q3 2024, with the low at $27.5 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $47.3 million (2024), against an average of $72.8 million.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 311.63% in 2024, then sank 42.14% in 2025.
• Arcutis Biotherapeutics' Total Current Liabilities stood at $37.8 million in 2022, then increased by 23.44% to $46.7 million in 2023, then jumped by 73.59% to $81.0 million in 2024, then jumped by 60.27% to $129.8 million in 2025, then rose by 25.7% to $163.2 million in 2026.
• Business Quant data shows ARQT's Total Current Liabilities at $163.2 million in Q1 2026, $129.8 million in Q4 2025, and $99.8 million in Q3 2025.